Clinical Trial: Tucatinib Plus Alpelisib in PIK3CA-Mutant, HER2+ Breast Cancer

Researchers are conducting a phase 1b/2 trial to test tucatinib plus alpelisib in patients with advanced, PIK3CA-mutant, HER2+ breast cancer.

Related Keywords

Colorado ,United States ,Denver ,Elena Shagisultanova ,Criterium Inc ,University Of Colorado ,Seagen Inc ,Novartis ,